Valorisation of ensiled fodder beets

Fodder beets (Beta vulgaris L.) are especially respected for their high feeding value and high netto-energy yield per hectare. The price per nutritive value is lowest as compared to other forages. Preservation of fodders beets demands thorough cleaning without damaging and regularly occurs as a whole in well closed piles. In addition, feeding them to the animals is labour demanding. These disadvantages enforce the research towards other preservation methods which may be able to valorise this valuable type of roughage. The preservation of fodder beets in silages using silo bags, either separately or in combination with maize was investigated. Fodder beets were harvested and ensilaged at the ideal moment of maize harvest (October) or fodder beets were harvested at the ideal moment for fodder beet harvest (November) and consequently ensilaged with previously ensilaged maize. Highest energy yields of the silages were recorded at optimal harvest time for fodder beets. Ensilaging fodder beets separately resulted in large energy losses due to effluent and dry matter losses. Using lab scale silage, possible solutions for these large losses were investigated. Addition of 10% maize did reduce the effluent losses but dry matter losses remained at a high level. Addition of 4,5 l propionic acid per ton beets reduced effluent and dry matter losses sufficiently. Ensilaging foliage was another point of interest. This appeared to result in a lowered energy yield at organic and dry matter basis, an increased amount of ashes and doubling of the iron (Fe) concentration.status: publishe

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.

Regulatory T cells (Tregs) are essential to prevent autoimmunity, but excessive Treg function contributes to cancer progression by inhibiting antitumor immune responses. Tregs exert contact-dependent inhibition of immune cells through the production of active transforming growth factor-β1 (TGF-β1). On the Treg cell surface, TGF-β1 is in an inactive form bound to membrane protein GARP and then activated by an unknown mechanism. We demonstrate that GARP is involved in this activation mechanism. Two anti-GARP monoclonal antibodies were generated that block the production of active TGF-β1 by human Tregs. These antibodies recognize a conformational epitope that requires amino acids GARP137-139 within GARP/TGF-β1 complexes. A variety of antibodies recognizing other GARP epitopes did not block active TGF-β1 production by Tregs. In a model of xenogeneic graft-versus-host disease in NSG mice, the blocking antibodies inhibited the immunosuppressive activity of human Tregs. These antibodies may serve as therapeutic tools to boost immune responses to infection or cancer via a mechanism of action distinct from that of currently available immunomodulatory antibodies. Used alone or in combination with tumor vaccines or antibodies targeting the CTLA4 or PD1/PD-L1 pathways, blocking anti-GARP antibodies may improve the efficiency of cancer immunotherapy